Andere Sprachen Keros Therapeutics, Inc.

Aktien

A2P2YF

US4923271013

KROS

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:08:35 01.05.2024			% 5 Tage	% 1. Jan.
58.48 ^USD	+3.70%		+2.83%	+45.45%

19.03.	Morphic Holding ernennt Simon Cooper zum Chief Medical Officer	MT
15.03.	Keros Therapeutics Aktien steigen nach FDA Fast Track Designation für potentielles Anämie-Medikament	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Morphic Holding Names Simon Cooper as Chief Medical Officer	19.03.
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug	15.03.
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug	14.03.
Keros Gets FDA Fast-Track Designation for Lead Drug KER-050	14.03.
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	14.03.
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	14.03.
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference	05.03.
Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024	05.03.
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	28.02.
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q4 Revenue $143,000	28.02.
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress	29.01.
Keros Therapeutics Closes $151.3 Million Stock Offering	09.01.
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock	09.01.
Keros Therapeutics Prices Stock Offering at $40 a Share	04.01.
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock	04.01.
Keros Therapeutics Proposes $120 Million Common Stock Offering	03.01.
Keros Therapeutics Announces Proposed Public Offering of Common Stock	03.01.
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Keros Therapeutics, Inc.

Aktien

A2P2YF

US4923271013

KROS

Andere Sprachen

Filter